rss
Br J Ophthalmol 2005;89:1616-1619 doi:10.1136/bjo.2005.072033
  • Clinical science
    • Extended reports

Systemic carboplatin for retinoblastoma: change in tumour size over time

  1. D H Abramson1,2,4,
  2. S D Lawrence2,
  3. K L Beaverson1,3,
  4. T C Lee1,2,
  5. I S Rollins1,
  6. I J Dunkel4
  1. 1Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  2. 2Department of Ophthalmology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA
  3. 3Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  4. 4Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  1. Correspondence to: David H Abramson MD, 70 East 66th Street, New York, NY 10021, USA; DHAMDaol.com
  • Accepted 1 August 2005

Abstract

Background/aim: Chemotherapy for intraocular retinoblastoma is used to shrink individual retinal tumours to a size amenable to focal treatments. Quantitative data regarding retinal tumour response following treatment with primary systemic carboplatin are reported.

Methods: Changes in area and largest basal diameter of tumours that were exposed to carboplatin, had no concomitant focal treatment, and had digital funduscopic photography performed before and after treatment, were measured. Response was evaluated.

Results: 36 tumours were measured following one treatment: 34/36 (94.4%) responded, with a 37.1% mean decrease in area (median  = 37.0%; range 4.0%–76.7%). Mean reduction in basal diameter was 21.3% (med = 21.0%; −7.9%–52.5%). 20 tumours were treated with a second cycle: 15/20 (75.0%) responded. Mean decrease in area was 17.8% (med = 15.3%; −7.0%–49.7%). The mean cumulative decrease in area after two treatments was 55.1% (med = 56.2%; 33.0%–74.5%). Mean cumulative reduction in basal diameter was 33.6% (med = 33.6%; 10.9%–53.2%). 12 tumours were treated with a third cycle: 3/12 (25.0%) responded, 8/12 were stable, and one progressed. Mean decrease in area was 5.4% (med = 7.2%; −17.7%–20.6%). Cumulative decrease in area after three treatments was 58.1% (med = 57.3%; 34.8%–77.2%). Mean cumulative reduction in basal diameter was 38.8% (med = 38.2%; 19.1%–54.1%).

Conclusions: Carboplatin caused measurable shrinkage of retinoblastoma tumours. Response was greatest following the initial treatment and decreased with subsequent treatments.

Footnotes

  • Supported in part by the Fund for Ophthalmic Knowledge, New York, NY, USA.

  • Competing interests: none declared

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.